Utilizing RNA interference to enhance cancer drug discovery.
With the development of RNA interference (RNAi) libraries, systematic and cost-effective genome-wide loss-of-function screens can now be carried out with the aim of assessing the role of specific genes in neoplastic phenotypes, and the rapid identification of novel drug targets. Here, we discuss the existing applications of RNAi in cancer drug discovery and highlight areas in this process that may benefit from this technology in the future.
Iorns
Elizabeth
E
The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.
Lord
Christopher J
CJ
Turner
Nicholas
N
Ashworth
Alan
A
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016158:Genes, p53; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D009857:Oncogenes; D034622:RNA Interference; D034741:RNA, Small Interfering; D013678:Technology, Pharmaceutical
D000970:Antineoplastic Agents; D034741:RNA, Small Interfering